总部设在瑞士巴塞尔的罗氏，是世界领先的、注重科研的医药和诊断产品开发集团之一。这个集团提供用于疾病的早期发现、预防、诊断和治疗的创新产品与服务，在广泛领域为人民健康与生活质量作出贡献。罗氏集团是诊断方面的世界领先公司，是治疗癌症和器官移植所需药品的领先提供商，也是病毒学方面的市场领先公司。2006年该集团药品部的销售总额为333亿瑞士法郎，诊断部的销售额为87亿瑞士法郎。罗氏集团在150个国家内拥有员工约75,000人，同许多伙伴订有研发协定并结成战略联盟，其中包括在美国基因技术公司（Genentech, Inc.）和日本中外製薬株式会社（Chugai Pharmaceutical Co., Ltd.）拥有多数股权。欲查询罗氏集团详情，请访问：www.roche.com。

　　罗氏—抗肿瘤领域的全球领先者

　　罗氏集团是唯一一家同时拥有5种已被证实能显著延长患者生存期抗肿瘤药物的公司。包括已在中国上市治疗HER2阳性乳腺癌的赫赛汀，治疗非霍奇金淋巴瘤的美罗华，治疗乳腺癌、结直肠癌、胃癌、胰腺癌的希罗达，非小细胞肺癌和胰腺癌治疗药物特罗凯，以及结直肠癌和非小细胞肺癌治疗药物AVASTIN。

　　罗氏的其他肿瘤产品还包括适用于各种癌性贫血的罗可曼和CERA，治疗肿瘤所致高钙血症、转移性骨痛和转移性骨病的邦罗力，针对放化疗所致恶心呕吐的凯特瑞，治疗白血病、卡波西肉瘤、恶性黑色素瘤、肾细胞癌的罗荛愫。以上这些产品对肿瘤治疗起到推动作用，造福更广大的患者。正如罗氏所言：“罗氏致力于健康事业的创新”。

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet at www.roche.com.

Roche in Oncology

The Roche Group, including its members Genentech in the United States and Chugai in Japan, is the world's leading provider of cancer care products, including anti-cancer treatments, supportive care products and diagnostics. Its oncology business includes an unprecedented five products proven to provide survival benefit in different major tumour indications: Avastin, Herceptin, and Xeloda in advanced-stage breast cancer, Herceptin in early-stage HER2-positive breast cancer, MabThera in non-Hodgkin's lymphoma, Avastin and Xeloda in colorectal cancer, Avastin and Tarceva in non-small cell lung cancer and Tarceva and Xeloda in pancreatic cancer.

Roche's supportive care medicines include NeoRecormon (anaemia in various cancer settings), Bondronat (metastatic bone disease), Kytril (for chemotherapy and radiotherapy-induced nausea and vomiting) and Neupogen (for cancer-related neutropenia).

In addition to the medicines, Roche is developing new diagnostic tests that will have a significant impact on disease management for cancer patients in the future. With a broad portfolio of tumour markers for prostate, colorectal, liver, ovarian, breast, stomach, pancreas and lung cancer, as well as a range of molecular oncology tests, Roche will continue to be one of the leaders in providing cancer-focused treatments and diagnostics.

Its unmatched oncology portfolio as well as an extensive external innovation base through collaborations with companies and academia are what makes it possible for Roche to provide more effective cancer therapies.

In the United States Herceptin, MabThera (Rituxan), Avastin and Tarceva are marketed either by Genentech alone or together with its partners Biogen Idec Inc. (MabThera) and OSI (Tarceva).

Outside of the United States, Roche and its Japanese partner Chugai are responsible for the marketing of these medicines.